Results 221 to 230 of about 42,521 (302)

Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease. [PDF]

Front Bioinform
Wong A, Guduri S, Chen T, Patel K.
europepmc   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Mechanisms and Production of Hypoglycaemic Peptides: Exploring the Potential of <i>Chlamydomonas reinhardtii</i>. [PDF]

Food Sci Nutr
Li Q, Su K, Yang C, Sun X, Huang J, Zhong S, Cheng LH.   +6 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. [PDF]

Mol Metab
Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J, Doerr J, Jarosch S, Lam D, Klein H, Pekcec A, Chehimi SN, Crist RC, Reiner BC, Hayes MR, Augustin R.   +15 more
europepmc   +1 more source

Complete Skin Remission of Lichen Planus With Tirzepatide

Australasian Journal of Dermatology, EarlyView.
Harmeet Bhullar, Emma Veysey, Tanya Bohl, Saurabh Prakash, Sarah Smithson   +4 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Incretin polyagonists as an alternative to bariatric surgery to manage obesity. [PDF]

World J Gastrointest Pathophysiol
Manoj RJ, Fernandez CJ, Nair S, Pappachan JM.   +3 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Integrated Genetic and Protein Mechanisms Underlying Glucagon-like Peptide-1 Receptor Agonists in Treating Diabetes Mellitus and Weight Loss. [PDF]

Curr Issues Mol Biol
Francis L, Butler MG.
europepmc   +1 more source